Drug intelligence / Profile preview

IGS03

Development stage: Preclinical
Lead developer: Ignis Therapeutics

Overview

IGS03 is an investigational therapeutic candidate being developed by Ignis Therapeutics for the treatment of Parkinson's Disease. As of early 2024, the program is in the preclinical stage of development. Ignis Therapeutics, a central nervous system (CNS) focused company established through a collaboration between SK Biopharmaceuticals and 6 Dimensions Capital, has not yet publicly disclosed the specific molecular target, modality, or mechanism of action for IGS03. The drug is part of a broader pipeline of CNS assets intended for the Chinese market and other regions.

Beyond the preview

Go deeper on IGS03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGS03.

Explore the full profile